My husband and I each have a DPhil from Oxford University. Mine is in Cell Physiology and his in Bio-Organic Chemistry. He has been working in pharmaceutical research for over 20 years. We invest in companies which have solid science, and avoid those whose science, we estimate, to be weak. We think that biotech companies can fail for many reasons; but none can succeed without solid science.
Disclaimer: My articles are meant to help, not to replace your own DD. They are not investment recommendations, and I am not an investment adviser. Biotech stocks are highly risky, volatile and speculative. Therefore, investing in these stocks may result in a partial or complete loss of investment. I write about what I consider as good long term investment opportunities (>10 years). Therefore, my articles may not be relevant or useful for those who have a shorter time frame or who are frequent traders. The disclosure statement in each article is accurate at the time of its publication. However, my personal portfolio can change at any time, without further notice.
Please conduct your own DD and consult your financial adviser before making any investment decisions, and take full responsibility for your own investment decisions and ensuing results.
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.
I am a retired baby boomer who enjoyed writing in my former profession. I have been an active investor and follower of the stock market for many years. Now that I am retired from my former profession I am enjoying writing for Seeking Alpha in an effort to join both interests into one new endeavor. Researching, generating a thesis, assembling a coherent interesting story, responding to highly favorable and highly critical comments provides for an unparalleled learning experience. For those so inclined, I highly recommend it. Writing under the pseudonym"out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned.
Seeking Alpha's product team is responsible for the development of all of our product-related projects from start to finish. These projects include the Seeking Alpha Portfolio apps on the App Store and Google Play, our Real Time email alert product, and optimization across the Seeking Alpha website.
The purpose of this profile is to allow us to share with our readers all new product developments. Please follow us on Seeking Alpha to receive updates. We look forward to your input and feedback!
SA Product Team
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I am a Physician (Board Certified in Child Psychiatry, Adult Psychiatry, and General Pediatrics) and I have been an investor in individual biotech companies for about 5 years. I first published on Seeking Alpha in 2014 and began writing regularly in mid 2017. My focus is finding value in Biotech companies while also reviewing technical aspects of their stocks. I concentrate on Neuroscience companies and share my perspective in this area.
You'll never see me write a long bio listing all of my credentials and degrees or refer to myself in the third person. I love discussing ideas and I appreciate it when people can play devil's advocate without resorting to personal attacks. In short, I employ a long-only, long-horizon, focused value style, guided by thorough bottom-up research and backed by years of accounting and finance experience. When people ask me "what do you do?" I assume they mean for fun.
Author of Beyond the Hype, a comprehensive emerging technology stock analysis and discussion service on Seeking Alpha Marketplace. Currently, we focus on identifying and investing in the renewable energy, storage, EV, autonomous vehicle, CPU, and GPU markets.
Beyond the Hype is different because it is dedicated to cutting through management and Wall Street commentary and providing fresh and insightful perspectives from a mid-market M&A consultant specializing in the technology and energy industries who's also been an individual Investor for over 25 years. The platform is about growth oriented investments primarily in market leaders and technology leaders. Investment philosophy is long term buy and hold with average holding time of several years.
Beyond the Hype is different because it is dedicated to cutting through management and Wall Street commentary and providing fresh and insightful perspectives on companies and investments. We see through hype, show the true value of companies, and make investments safer. A lot of views tend to be controversial, against the grain, and remarkably accurate.
In investing, people typically talk about high risk, high reward. At Beyond The Hype, we would like to do a little better. Our motto is: Low Risk, High Reward
I currently help students understand fundamental analysis of equities and how to explore the use of Bloomberg terminals for doing meaningful research. Recently I've been covering cryptocurrencies more because the field is exciting and not well researched. I've slowed my writing on stocks due to the nature of my investment process. I look at earnings transcripts, do ratio analysis and sentiment analysis, and look at price action before I buy. These are often not enough to fill a detailed article like the ones I was writing and I would rather not publish weak pieces. I still hope to give my insights on equities occasionally (likely through blog posts), but will be moving to cover the CryptoSphere more. If you're interested in cryptocurrencies, even just to learn more, I hope you'll stick around!
Formerly a Wall Street executive from a premier investment bank, author EXP's goal is to help investors discover stocks before the "crowd." The first article published was on "LNG" many years ago; an undiscovered gem. BLOG: https://seekingalpha.com/account/authorboard/instablog
This is not an easy business. Investing is psychological in nature and can be extremely taxing. Patience is key. Not all ideas are written about or picked for publication.
EXP works hard to identify and write about current stock opportunities in the market that can produce some huge gains from disconnects in stock prices. These inefficiencies can be taken advantage of if you can properly identify opportunities, and then manage to act on them before the crowd.
EXP resides in the USA and is very thankful to followers worldwide.
You can also follow EXPstocktrader on: Twitter --- @EXPstocktrader Email --- email@example.com >>>
Disclosure: The administrator(s) of the services mentioned here may be long, short, or flat in any position mentioned as disclosed. All statements are made without any representation to its complete accuracy and administrator(s) are not compensated for posting notes by listed companies. Some minimal compensation is paid by SA if the article gets picked for circulation. EXP never takes money from companies to promote or write about a stock. All stock prices shown are approximate. Ratings may change at any time. All posts are for simulation purposes only. All stock trades transacted by you are at your own risk. We trade stocks and do not usually buy and hold indefinitely. Please take any information that you see here and consult your own investment advisor before making any real trades. EXP, EXPstocktrader and Seeking Alpha are Not licensed to give you investment advice based on your own personal suitability and risk tolerances. Please consult with your financial advisor before making any trades that you read about here or anywhere EXPstocktrader publishes information for that matter. Thank you.
Semi-retired. 40 years experience in biotech industry, as scientist, inventor, research director, consultant, expert witness, and Board of Directors member, as well as long time investor in biotech, including private equity, LLCs, and joint ventures. Currently, Expert Consultant in biotechnology, intellectual property, patents, molecular genetics, genomics, RNA silencing, RNA interference, epigenetics, bioinformatics and cyber infrastructure. Professor Emeritus at University of Arizona.
Individual Investor with a preference for long-term value-oriented investments that are based on in-depth research & understanding of the company's products and markets. Educational background includes mechanical engineering and MBA (Finance) degrees.
I come from a background of Electrical Engineering. I enjoyed the creativity of working in the high-tech industry for 24 years, in design and managerial positions. In 2013 I decided to take a few years off from high-tech work, and concentrate on other areas of interest, including investing and stock analysis. I mostly invest in technology, and biotech, which I believe is the next revolution that is already underway, like computers were 20-50 years ago.
I hold a PhD in Electrical Engineering (Control Theory) from Stanford University and a Masters Degree in Engineering-Economic Systems (now called Management Science and Engineering at Stanford).
I have been fascinated by the stock market since I was 14 (that is 37 years ago at writing). It has always struck me as the place to be.
In the last 10+ years I moved from what I would call the "herd mentality" to a more educated process. In particular, my years as a Principal Software Engineer in a derivatives software development company, interacting closely with Financial Engineers, showed me clearly the simple science behind this: "Mean Reversion is All We Know about the Game!"
Long-time individual investor who began trading in mid-90's. My philosophy is to identify "value gaps" between what I believe a company to be worth today versus it's stock price. I do not follow charts or technicals, but rather look to find companies with stock prices that move out of sync with the value of recent news to find and (hopefully) capitalize on these value gaps.
Over 35 years of investing in individual stocks. Extensive business experience with small to mid-size companies, including as CEO. Many hundreds of blog posts on financial and economic matters since 2008. Focus on value with catalysts for upside price action; and biotech. Background as a physician and pharmaceutical inventor and entrepreneur.